FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Immunomedics, Inc. patents


      
Recent patent applications related to Immunomedics, Inc.. Immunomedics, Inc. is listed as an Agent/Assignee. Note: Immunomedics, Inc. may have other listings under different names/spellings. We're not affiliated with Immunomedics, Inc., we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics, Inc.-related inventors



Search recent Press Releases: Immunomedics, Inc.-related press releases
Count Application # Date Immunomedics, Inc. patents (updated weekly) - BOOKMARK this page
12015001851601/15/15Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
22014037717312/25/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
32014037717712/25/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
42014037728712/25/14Anti-trop-2 antibody-drug conjugates and uses thereof
52014036992712/18/14Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
62014028686009/25/14Immunoconjugates with an intracellularly-cleavable linkage
72014028686109/25/14Rs7 antibodies
82014023420908/21/14Chimeric and humanized anti-histone antibodies
92014022717808/14/14Humanized anti-hla-dr antibodies
102014022717908/14/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
112014022718008/14/14Antibody-sn-38 immunoconjugates with a cl2a linker
122014022854108/14/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
132014021991408/07/14Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
142014021995608/07/14Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
152014021242507/31/14Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
162014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
172014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
182014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
192014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
202014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
212014014092405/22/14Humanized l243 antibodies
222014012003505/01/14Rs7 antibodies
232014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
242014011286504/24/14Anti-cd19 antibodies
252014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
262014009925804/10/14Camptothecin-binding moiety conjugates
272014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
282014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
292014007962903/20/14Class i anti-cea antibodies and uses thereof
302014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
312014004463902/13/14Antibody therapy
322014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
332014003754302/06/14Anti-pancreatic cancer antibodies
342014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
352014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
362014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
372014001719701/16/14Anti-cd19 antibodies
382014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
392013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
402013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
412013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
422013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
432013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
442013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
452013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
462013017106407/04/13Anti-cd74 immunoconjugates and methods of use
472013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
482013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
492013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
502013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
512013015669106/20/13Antibody therapy
522013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
532013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
542013012191305/16/13Anti-cd19 antibodies
552013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
562013009503404/18/13Anti-cd74 immunoconjugates and methods
572013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
582013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
592013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
602013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
612013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
622013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
632013003986102/14/13Dye conjugated peptides for fluorescent imaging
642013003449202/07/13Class i anti-cea antibodies and uses thereof
652012032856412/27/12Camptothecin-binding moiety conjugates
662012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
672012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
682012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
692012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
702012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
712012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
722012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
732012018954207/26/12Anti-cd19 antibodies
742012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
752012018355007/19/12Therapeutic using a bispecific antibody
762012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
772012014137206/07/12Rs7 antibodies
782012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
792012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
802012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
812012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
822012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
832012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
842012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
852012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
862012003979702/16/12Antibody therapy
872012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
882012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
892011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
902011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
912011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
922011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
932011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
942011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
952011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
962011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
972011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
982011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
992011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1002011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1012011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1022011022364509/15/11Multivalent carriers of bi-specific antibodies
1032011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1042011018908508/04/11Antibody therapy
1052011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1062011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1072011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1082011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1092011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1102011011710505/19/11Method of treating immune disease using b-cell antibodies
1112011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1122011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1132011007015503/24/11Anti-cd74 immunoconjugates and methods
1142011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1152011006465303/17/11Class i anti-cea antibodies and uses thereof
1162011005248903/03/11Anti-cd19 antibodies
1172010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1182010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1192010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1202010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1212010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1222010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1232010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1242010022117509/02/10Antibody therapy
1252010022117709/02/10Rs7 antibodies
1262010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1272010020296108/12/10D-amino acid peptides
1282010019626608/05/10Humanized anti-hla-dr antibodies
1292010019626708/05/10Humanized l243 antibodies
1302010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1312010018964107/29/10Novel strategies for improved cancer vaccines
1322010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1332010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1342010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1352010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1362010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1372010006813603/18/10Anti-cd19 antibodies
1382010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1392010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1402010001504601/21/10Camptothecin-binding moiety conjugates
1412010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1422010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1432010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1442009030458012/10/09Anti-pancreatic cancer antibodies
1452009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1462009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1472009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1482009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1492009025273110/08/09Multivalent carriers of bi-specific antibodies
1502009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1512009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1522009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1532009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1542009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1552009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1562009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1572009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1582009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1592009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1602009009259804/09/09Antibody therapy
1612010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1622010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules


ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE